UEG Week 2022

Personalized therapy - de-escalation strategies

The benefit of early intervention in CD

Is IL-23 the super target?

What is the best dose of adalimumab in CD?

What is new in anti-TNFα therapy?

Treat-to-target with ustekinumab - why didn't it work?

Treat-to-target still alive?

Longterm potential benefit of a combIo therapy

T reg - a new therapeutic target in IBD?

Once more a shocking message: be aware of steroids!

You can still treat severe biofailure in CD

Thinking out of the box - co-medication of the elderly

Treat-to-target strategy is superior to conventional step-care in active patients to gain remission

Combination therapy: week 38 efficacy and safety data from the VEGA study

No matter what you use - treat early!

Explosion of new drugs

Pharmacokinetics of ustekinumab in the STARDUST trial

TYK2 Deucravacitinib in ulcerative colitis

Enhanced treatment algorithm for the management of CD

Anti-IL-23 monoclonal antibodies: is it better to target IL-23 only than IL-23 and IL-12?

Treating the patient as a whole

Small molecules in crohn's disease

Oral anti-integrin therapy in IBD - new data, new chances?

Postoperative monitoring matters!

VEGA - the story continues

Terapia di combinazione: efficacia e sicurezza a 38 settimane nello studio VEGA

Anticorps anti-IL-23: est-il préferabble de cibler l'IL-23 seule plutôt que l'IL-12 et l'IL-23?

Explosión de nuevos fármacos

T reg - nowy cel terapeutyczny w IBD?

Small molecules nel morbo di crohn

Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα κορτικοστεροιδή!

Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!

Doustna terapia antyintegrynowa - nowe dane, nowe nadzieje?

Thinking out of the box - Einfluss der Begleitmedikation bei älteren Patienten

Was tun nach der Operation?

Les résultats à long terme d'une combIothérapie

Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά νόσο του Crohn

TYK2 Deucravacitinib bei Colitis ulcerosa

VEGA - l'histoire continue

Una strategia “Treat-to-target” è superiore rispetto and un approccio convenzionale nel raggiungimento della remissione in pazienti con malattia attiva

Treating the patient as a whole

Update on IL-23 inhibition in UC

S1P receptor modulators

1st JAK inhibitor in CD - a game changer?

Update on JAK inhibition in UC

JAK-inhibition

Final efficacy and safety results from Upadacitinib 52 weeks maintenance trial in UC patients

Selective IL-23 blockade

The era of small molecules

Persistance on therapy and real-world clinical effectiveness of Tofacitinib in ulcerative colitis: data from the ENEIDA registry

The 1st JAKi in CD

Ozanimod works in young and old UC patient

Upadacitinib maintenance therapy - final results from U-ACHIEVE

VEGA & LUCENT studies

Estrasimod in moderate to severe active UC

Upadacitinib - induction therapy in CD

Histological response and remission induced by mirikizumab

Risankizumab in refractory CD patients

Persistenza in terapia ed efficaci clinica di Tofacitinib in colite ulcerosa: dati dal registro ENEIDA

Upadacitinib - Induktionsdaten bei CD

The area of small molecules

JAK-Inhibition

Risultati finali di efficacia e sicurezza a 52 settimane di Upadacitinib in colite ulcerosa

Risankizumab dans la maladie de Crohn réfractaire

VEGA & LUCENT studi clinici

Selective IL-23 Blockade

Treating the elderly - closer surveillance and the importance of co-medication

Updated safety data on JAK inhibitors

Steroid effects as treatment goals: quality of life and steroid free remission

Urgency - putting the focus on an important endpoint!

Filgotinib is efficacious in inducing and maintaining histological remission in UC

Urgency matters!

Patient reported outcomes in IBD

New endpoints in IBD

Patienten gerichtete Endpunkte bei CED

Neue Studienendpunkte in IBD

Whats's the origin of Crohn's genetics ? The history of IL-23 receptor genetics in Europe

Explosion of Spanish contributions

Explosión de las comunicaciones españolas

Wo kommt die Crohn-Genetik her? Die Historie der IL-23 Rezeptorgenetik in Europa

Personalised therapy in IBD

Individualisierte Therapie bei CED